Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC).
Andrew James Weickhardt
Honoraria - Pfizer
Benjamin Scheier
No relevant relationships to disclose
Joseph Malachy Burke
No relevant relationships to disclose
Gregory Gan
No relevant relationships to disclose
Robert Charles Doebele
Honoraria - Abbott Laboratories; Pfizer
Research Funding - ImClone Systems; Lilly; Pfizer
Paul A. Bunn
Employment or Leadership Position - IASLC
Consultant or Advisory Role - Agennix; Amgen; AstraZeneca; Bayer; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; GlobeImmune; Lilly; Merck; Merrimack; Novartis; OSI Pharmaceuticals; Pfizer; Roche/Genentech; Sanofi
Honoraria - Agennix; Amgen; AstraZeneca; Bayer; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; GlobeImmune; Lilly; Merck; Merrimack; Novartis; OSI Pharmaceuticals; Pfizer; Roche/Genentech; Sanofi
Laurie E. Gaspar
No relevant relationships to disclose
Brian D. Kavanagh
No relevant relationships to disclose
D. Ross Camidge
Consultant or Advisory Role - Astellas Pharma; OSI Pharmaceuticals; Pfizer
Honoraria - Pfizer
Research Funding - Pfizer